company background image
HEM logo

Hemostemix TSXV:HEM Stock Report

Last Price

CA$0.29

Market Cap

CA$40.8m

7D

-22.4%

1Y

195.0%

Updated

04 Feb, 2025

Data

Company Financials

HEM Stock Overview

A clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. More details

HEM fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Hemostemix Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Hemostemix
Historical stock prices
Current Share PriceCA$0.29
52 Week HighCA$0.42
52 Week LowCA$0.035
Beta0.18
1 Month Change136.00%
3 Month Change227.78%
1 Year Change195.00%
3 Year Change110.71%
5 Year Change47.50%
Change since IPO-98.03%

Recent News & Updates

Recent updates

Shareholder Returns

HEMCA BiotechsCA Market
7D-22.4%4.7%-0.7%
1Y195.0%12.6%16.9%

Return vs Industry: HEM exceeded the Canadian Biotechs industry which returned 11.6% over the past year.

Return vs Market: HEM exceeded the Canadian Market which returned 16.9% over the past year.

Price Volatility

Is HEM's price volatile compared to industry and market?
HEM volatility
HEM Average Weekly Movement35.7%
Biotechs Industry Average Movement13.8%
Market Average Movement8.4%
10% most volatile stocks in CA Market18.4%
10% least volatile stocks in CA Market3.0%

Stable Share Price: HEM's share price has been volatile over the past 3 months compared to the Canadian market.

Volatility Over Time: HEM's weekly volatility has increased from 29% to 36% over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/an/aThomas Smeenkhemostemix.com

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.

Hemostemix Inc. Fundamentals Summary

How do Hemostemix's earnings and revenue compare to its market cap?
HEM fundamental statistics
Market capCA$40.79m
Earnings (TTM)-CA$1.99m
Revenue (TTM)n/a

0.0x

P/S Ratio

-20.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HEM income statement (TTM)
RevenueCA$0
Cost of RevenueCA$0
Gross ProfitCA$0
Other ExpensesCA$1.99m
Earnings-CA$1.99m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.014
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio-55.1%

How did HEM perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/04 13:02
End of Day Share Price 2025/02/04 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hemostemix Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Siddharth RajeevFundamental Research Corp.